Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 363, Issue 3, Pages 846-851Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2007.09.043
Keywords
Parkinson's disease; inclusion; renin-angiotensin-system; synuclein; synphilin-1; angiotensin; AT receptor; losartan; PD123319
Categories
Funding
- NINDS NIH HHS [2P50NS038372-06A1, P50 NS038372-06A1, P50 NS038372] Funding Source: Medline
Ask authors/readers for more resources
In this study, we examined the effects of angiotensin If (AngII) in a genetic in vitro PD model produced by alpha-synuclein (ot-syn) overexpression in the human neuroglioma H4 cell line. We observed a maximal decrease in alpha-syn-induced toxicity of 85% and reduction in inclusion formation by 19% when cultures were treated with AngII in the presence of the angiotensin type I (AT]) receptor antagonist losartan and AT2 receptor antagonist PD123319. When compared to AngII, the AT4 receptor agonist AngIV was moderately effective in protecting H4 cells against alpha-syn toxicity and did not significantly reduce inclusion formation. Here we show that AngII is protective against genetic, as well as neurotoxic models of PD. These data support the view that agents acting on the renin-angiotensin-system (RAS) may be useful in the prevention and/or treatment of Parkinson's disease. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available